Benefits of Early SAVR for Asymptomatic Aortic Stenosis Persist a Decade On

Patients with asymptomatic severe aortic stenosis (AS) live longer and avoid more heart-failure hospitalizations when they choose early surgical aortic valve replacement (SAVR) instead of waiting for symptoms.

Why Early SAVR Wins Long-Term

Final 10-year results from the RECOVERY trial and NEJM publication show immediate SAVR slashed the composite of operative mortality or cardiovascular death from 24% (conservative care) to 3% (early surgery; HR 0.10). All-cause mortality dropped to 15% versus 32%, with zero operative deaths in either group. Benefits held steady over a median 12 years, yielding a number needed to treat of 6 to avert one CV death and 7 for any death.

RECOVERY Trial Essentials

The trial randomized 145 truly asymptomatic patients (mean age ~64 years) with very severe AS—aortic valve area ≤ 0.75 cm² plus peak velocity ≥ 4.5 m/s or mean gradient ≥ 50 mm Hg—to early SAVR (within 2 months) or conservative care with AVR for symptoms, LVEF < 50%, or rapid progression. 85% of conservative patients eventually needed AVR (mostly SAVR), but faced higher CV and all-cause death plus 19% heart-failure hospitalizations (vs 0% early).

Fits With Broader Evidence

RECOVERY aligns with AVATAR, EARLY TAVR, and EVOLVED, all backing early intervention in asymptomatic severe AS. Its younger, low-comorbidity cohort with bicuspid valves and extreme gradients likely drove the stark survival gap. ESC and ACC/AHA guidelines endorse class IIa for early AVR in low-risk cases with peak velocity > 5.0 m/s, rapid change, or elevated BNP.

Shared Decision-Making Guide

Frame discussions around prosthetic valve risks (degeneration, thromboembolism, bleeding) versus irreversible LV damage from prolonged overload. Watchful waiting suits vigilant patients who report symptoms promptly; early SAVR/TAVR appeals to those prioritizing proven long-term gains. Trials like EASY-AS will refine for elderly, comorbid patients often undertreated today.

To-Do List in Office Visit for Patient with Asymptomatic Severe AS

Use this prioritized checklist for a practicing cardiologist seeing a patient like those in the RECOVERY trial—asymptomatic, very severe AS (peak velocity ≥ 4.5 m/s, AVA ≤ 0.75 cm², mean gradient ≥ 50 mm Hg).

• Confirm diagnosis via recent echo review: Verify severe AS criteria, assess LVEF ≥ 50%, check LV geometry, pulmonary pressures, and serial progression (e.g., Vmax increase ≥ 0.3-0.5 m/s/year).

• Assess true asymptomatic status: Probe for subtle exertional dyspnea, fatigue, or reduced exercise tolerance using standardized questionnaire; review patient diary if available.

• Order exercise stress test if not done: Look for valve-related symptoms, abnormal BP response (fall >10 mm Hg), or low exercise capacity—class I/IIa trigger for AVR per ESC/ACC guidelines.

• Quantify risk markers: Measure BNP/NT-proBNP (elevated = class IIa for AVR); consider CT calcium score if low-gradient; evaluate coronary anatomy via CT angio or invasive if indicated.

• Calculate surgical risk: Use STS score or EuroSCORE II; confirm low risk (<1-2% mortality) for class IIa early AVR recommendation if Vmax > 5.0 m/s.

• Discuss RECOVERY evidence: Share 10-year data (3% vs 24% CV death with early SAVR); highlight NNT 6-7 and zero HF hospitalizations in early arm.

• Engage in shared decision-making: Weigh early SAVR/TAVR benefits (survival, QOL) vs watchful waiting risks (sudden death, irreversible LV damage); address prosthesis durability, bleeding/anticoagulation.

• Plan surveillance if deferring: Schedule echo every 6 months; symptom check-ins q3 months; educate on red flags (new dyspnea, syncope); immediate AVR if LVEF drops <50-60%.

• Refer to Heart Team: Consult CT surgery, interventional, imaging for SAVR vs TAVR eligibility; document discussion in notes.

• Follow up promptly: Book return in 4-6 weeks post-testing; update guidelines (e.g., 2025 ESC/EACTS, 2020/updated ACC/AHA).